Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.51) by 23.53 percent. This is a 37.1 percent increase over losses of $(0.62) per share from the same period last year.